Hartline Investment Corp’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-316,331
| Closed | -$13.1M | – | 111 |
|
|
2023
Q2 | $13.1M | Buy |
316,331
+11,430
| +4% | +$710K | 2.24% | 12 |
|
|
2023
Q1 | $18.3M | Buy |
304,901
+419
| +0.1% | +$33.5K | 3.66% | 7 |
|
|
2022
Q4 | $22.3M | Buy |
+304,482
| New | +$22.9M | 5.08% | 4 |
|
|
2022
Q3 | – | Sell |
-335,191
| Closed | -$58M | – | 197 |
|
|
2022
Q2 | $58M | Buy |
335,191
+32,997
| +11% | +$2.49M | 8.32% | 2 |
|
|
2022
Q1 | $67M | Sell |
302,194
-15,915
| -5% | -$1.17M | 8.47% | 2 |
|
|
2021
Q4 | $23.9M | Buy |
318,109
+11,986
| +4% | +$1.2M | 3.27% | 9 |
|
|
2021
Q3 | $35.6M | Buy |
306,123
+3,929
| +1% | +$594K | 4.95% | 4 |
|
|
2021
Q2 | $67M | Sell |
302,194
-23,612
| -7% | -$4.59M | 8.47% | 2 |
|
|
2021
Q1 | $43.1M | Sell |
325,806
-9,385
| -3% | -$1.48M | 6.55% | 2 |
|
|
2020
Q4 | $58M | Sell |
335,191
-395
| -0.1% | -$54.1K | 8.32% | 2 |
|
|
2020
Q3 | $37.4M | Sell |
335,586
-1,031
| -0.3% | -$82.4K | 6.31% | 3 |
|
|
2020
Q2 | $20M | Buy |
336,617
+6,454
| +2% | +$424K | 4.18% | 6 |
|
|
2020
Q1 | $22.2M | Sell |
330,163
-509
| -0.2% | -$40.2K | 5.55% | 3 |
|
|
2019
Q4 | $27.9M | Buy |
330,672
+216
| +0.1% | +$17.4K | 5.97% | 3 |
|
|
2019
Q3 | $24.7M | Sell |
330,456
-5,129
| -2% | -$410K | 5.94% | 2 |
|
|
2019
Q2 | $21.2M | Sell |
335,585
-6,870
| -2% | -$348K | 5.07% | 2 |
|
|
2019
Q1 | $16.5M | Sell |
342,455
-62,611
| -15% | -$3.01M | 4.31% | 3 |
|
|
2018
Q4 | $13.6M | Sell |
405,066
-4,540
| -1% | -$166K | 4.13% | 3 |
|
|
2018
Q3 | $21.5M | Sell |
409,606
-5,323
| -1% | -$212K | 5.02% | 2 |
|
|
2018
Q2 | $13M | Buy |
414,929
+10,877
| +3% | +$303K | 3.5% | 4 |
|
|
2018
Q1 | $8.81M | Buy |
404,052
+13,579
| +3% | +$292K | 2.42% | 9 |
|
|
2017
Q4 | $7.89M | Buy |
390,473
+22,306
| +6% | +$430K | 2.18% | 9 |
|
|
2017
Q3 | $7.31M | Sell |
368,167
-2,168
| -0.6% | -$42.6K | 2.21% | 9 |
|
|
2017
Q2 | $6.41M | Buy |
370,335
+188,774
| +104% | +$2.44M | 2.04% | 12 |
|
|
2017
Q1 | $1.47M | Sell |
181,561
-14,287
| -7% | -$103K | 0.47% | 54 |
|
|
2016
Q4 | $1.54M | Buy |
195,848
+54,907
| +39% | +$442K | 0.54% | 50 |
|
|
2016
Q3 | $1.2M | Buy |
140,941
+57,751
| +69% | +$527K | 0.43% | 55 |
|
|
2016
Q2 | $971K | Sell |
83,190
-400
| -0.5% | -$5.01K | 0.35% | 57 |
|
|
2016
Q1 | $1.21M | Buy |
83,590
+32,450
| +63% | +$466K | 0.44% | 49 |
|
|
2015
Q4 | $1.14M | Buy |
+51,140
| New | +$1.22M | 0.43% | 52 |
|
Other funds holding NVCR
DTC
Hartline Investment Corp's NVCR Position: Q3 2023 in Review
Hartline Investment Corp sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 316,331 shares — an estimated $13.1M sold.
Hartline Investment Corp first reported a position in NVCR in Q4 2015 and held it in 30 quarters. The position peaked at $67M in Q1 2022. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.
- Hartline Investment Corp reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
- Hartline Investment Corp sold 316,331 NovoCure shares in Q3 2023, an estimated $13.1M.
- Hartline Investment Corp first reported a position in NovoCure in Q4 2015 and held it in 30 quarters.
- Hartline Investment Corp's NovoCure position peaked at $67M in Q1 2022.
- 226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.
Based on Hartline Investment Corp's 13F filing for Q3 2023, filed 3 Nov 2023.